JW Pharmaceutical Corp (001067) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.132x

Based on the latest financial reports, JW Pharmaceutical Corp (001067) has a cash flow conversion efficiency ratio of 0.132x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩46.92 Billion ≈ $31.79 Million USD) by net assets (₩354.10 Billion ≈ $239.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 001067 equity financing ratio to measure how much of total assets are equity-financed.

JW Pharmaceutical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how JW Pharmaceutical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check JW Pharmaceutical Corp earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

JW Pharmaceutical Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of JW Pharmaceutical Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Avon Protection PLC LSE:AVON	0.014x
enVVeno Medical Corp NASDAQ:NVNO	-0.149x
The North American Income Trust plc LSE:NAIT	0.019x
Scandinavian Brake Systems A/S CO:SBS	-0.012x
Wahana Inti MakmurTbk PT JK:NASI	0.004x
Comprehensive Healthcare Systems Inc V:CHS	-0.033x
Triton Development S.A. WAR:TRI	-0.031x
James Halstead PLC LSE:JHD	0.106x

Annual Cash Flow Conversion Efficiency for JW Pharmaceutical Corp (2014–2024)

The table below shows the annual cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see JW Pharmaceutical Corp (001067) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩329.49 Billion ≈ $223.29 Million	₩79.39 Billion ≈ $53.80 Million	0.241x	-26.62%
2023-12-31	₩265.44 Billion ≈ $179.89 Million	₩87.16 Billion ≈ $59.07 Million	0.328x	+30.59%
2022-12-31	₩225.76 Billion ≈ $152.99 Million	₩56.76 Billion ≈ $38.47 Million	0.251x	+161.57%
2021-12-31	₩188.54 Billion ≈ $127.77 Million	₩18.12 Billion ≈ $12.28 Million	0.096x	-68.37%
2020-12-31	₩207.47 Billion ≈ $140.60 Million	₩63.05 Billion ≈ $42.73 Million	0.304x	+25.93%
2019-12-31	₩230.09 Billion ≈ $155.93 Million	₩55.53 Billion ≈ $37.63 Million	0.241x	+20.47%
2018-12-31	₩260.11 Billion ≈ $176.27 Million	₩52.11 Billion ≈ $35.31 Million	0.200x	+62.17%
2017-12-31	₩270.78 Billion ≈ $183.50 Million	₩33.45 Billion ≈ $22.67 Million	0.124x	+406.54%
2016-12-31	₩276.31 Billion ≈ $187.25 Million	₩6.74 Billion ≈ $4.57 Million	0.024x	+231.67%
2015-12-31	₩225.41 Billion ≈ $152.75 Million	₩-4.17 Billion ≈ $-2.83 Million	-0.019x	-155.99%
2014-12-31	₩220.02 Billion ≈ $149.11 Million	₩7.28 Billion ≈ $4.93 Million	0.033x	--

About JW Pharmaceutical Corp

KO:001067 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$6.11 Million

₩9.01 Billion KRW

Market Cap Rank

#28160 Global

#2067 in Korea

Share Price

₩43600.00

Change (1 day)

+0.00%

52-Week Range

₩41000.00 - ₩63700.00

All Time High

₩131401.16